Published in Ann Pharmacother on September 01, 1994
Current concepts in the pathogenesis and treatment of chronic suppurative otitis media. J Med Microbiol (2015) 1.01
A study of the bacteriological profile of chronic suppurative otitis media in agartala. Indian J Otolaryngol Head Neck Surg (2011) 0.86
Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf (2000) 2.37
Efficacy of diazepam and meperidine in ambulatory pediatric patients undergoing endoscopy: a randomized, double-blind trial. J Pediatr Gastroenterol Nutr (1993) 2.19
The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother (1992) 2.13
Once-daily administration of aminoglycosides. Ann Pharmacother (1994) 1.73
Teaching paediatric pharmacotherapy at colleges of pharmacy in the United States and Canada. J Clin Pharm Ther (1994) 1.48
Issues facing clinical pharmacy education for undergraduate students. DICP (1989) 1.40
Standard room temperature needed for stability and compatibility studies. Am J Hosp Pharm (1993) 1.39
Role of the ketogenic diet in children with intractable seizures. Ann Pharmacother (1998) 1.39
Treatment of listeriosis. Ann Pharmacother (2000) 1.32
Need for conducting research on medications unlabeled for use in pediatric patients. Ann Pharmacother (1994) 1.30
Clinical use of systemic antifungal agents. Clin Pharm (1988) 1.23
Clinical pharmacokinetics of antibacterial drugs in neonates. Clin Pharmacokinet (1990) 1.21
Chloramphenicol serum concentration falls during chloramphenicol succinate dosing. Clin Pharmacol Ther (1983) 1.16
Glycerol: a review of its pharmacology, pharmacokinetics, adverse reactions, and clinical use. Pharmacotherapy (1986) 1.12
Pediatric drug formulations: challenges and potential solutions. Ann Pharmacother (1999) 1.09
Pharmacokinetics of amphotericin B in children. Antimicrob Agents Chemother (1989) 1.07
Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants. Eur J Clin Pharmacol (1988) 1.05
Complication of intranasal midazolam. Pediatrics (1993) 1.03
Treatment and prevention of infections of cerebrospinal fluid shunts. Clin Pharm (1987) 1.03
Positive impact of a therapeutic drug-monitoring program on total aminoglycoside dose and cost of hospitalization. Ther Drug Monit (1987) 1.02
Pathogenesis and treatment of bronchiolitis. Clin Pharm (1993) 0.99
Nelfinavir mesylate: a protease inhibitor. Ann Pharmacother (1999) 0.96
Variation in morphine pharmacokinetics in children with cancer. Dev Pharmacol Ther (1985) 0.95
A comparative review of conventional and lipid formulations of amphotericin B. J Clin Pharm Ther (1999) 0.95
Acetaminophen accumulation in pediatric patients after repeated therapeutic doses. Eur J Clin Pharmacol (1984) 0.95
Lack of nephrotoxicity in pediatric patients receiving concurrent vancomycin and aminoglycoside therapy. Chemotherapy (1987) 0.95
Adverse effects of meperidine, promethazine, and chlorpromazine for sedation in pediatric patients. Clin Pediatr (Phila) (1985) 0.94
Effect of gestational age and birth weight on tobramycin kinetics in newborn infants. J Antimicrob Chemother (1984) 0.94
Antimicrobial dosages in guidelines for prevention of bacterial endocarditis. Clin Pharm (1991) 0.94
Determination of cefaclor by high-performance liquid chromatography. J Chromatogr (1982) 0.94
Pharmacokinetics of dexamethasone in premature neonates. Eur J Clin Pharmacol (1996) 0.93
Clinical use of trimethoprim/sulfamethoxazole during renal dysfunction. DICP (1989) 0.93
Ganciclovir--a review of pharmacology, therapeutic efficacy and potential use for treatment of congenital cytomegalovirus infections. J Clin Pharm Ther (1989) 0.93
Efficacy of amlodipine in pediatric patients with hypertension. Pediatr Nephrol (1999) 0.92
Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. Ann Pharmacother (1995) 0.92
Pharmacokinetics of cefuroxime axetil suspension in infants and children. Antimicrob Agents Chemother (1991) 0.91
Effect of infusion methods on tobramycin serum concentrations in newborn infants. J Pediatr (1984) 0.91
Oral terbinafine: a new antifungal agent. Ann Pharmacother (1997) 0.90
Delivery of tobramycin by three infusion systems. Chemotherapy (1984) 0.89
Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Chest (1997) 0.89
Efficacy and safety of aerosolized tobramycin in cystic fibrosis. Pediatr Pulmonol (2001) 0.89
Pharmacokinetics of netilmicin in premature infants. Eur J Clin Pharmacol (1986) 0.88
Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate. Clin Pharmacol Ther (1981) 0.87
Research productivity and funding. DICP (1991) 0.87
Bacterial contamination of aerosol solutions used to treat cystic fibrosis. Am J Hosp Pharm (1982) 0.87
Sulbactam/ampicillin, a new beta-lactamase inhibitor/beta-lactam antibiotic combination. Drug Intell Clin Pharm (1988) 0.85
Pharmacokinetics of phenytoin in children with acute neurotrauma. Crit Care Med (1995) 0.85
Treatment of irritable bowel syndrome. J Clin Pharm Ther (2010) 0.85
Clinical uses of fentanyl, sufentanil, and alfentanil. Clin Pharm (1991) 0.84
Efficacy of ototopical ciprofloxacin in pediatric patients with otorrhea. Otolaryngol Head Neck Surg (1997) 0.84
Effect of ascorbic acid on urine pH in man. Am J Hosp Pharm (1977) 0.84
Interlot variability in gentamicin and tobramycin concentration and its possible significance. Ther Drug Monit (1986) 0.84
Pharmacologic management of patent ductus arteriosus. Clin Pharm (1989) 0.83
Treatment of pediatric hypertension. Pharmacotherapy (2000) 0.83
Moxalactam epimer kinetics in children. Clin Pharmacol Ther (1982) 0.82
Cephalexin pharmacokinetics in patients with cystic fibrosis. Dev Pharmacol Ther (1984) 0.82
Interactions among chloramphenicol, phenytoin, and phenobarbital in a pediatric patient. J Pediatr (1981) 0.82
Gastrostomy tube placement in nonadherent HIV-infected children. Ann Pharmacother (2001) 0.82
Tobramycin pharmacokinetics in very low birth weight infants. Br J Clin Pharmacol (1986) 0.82
Periorbital cellulitis secondary to Conidiobolus incongruus. Pharmacotherapy (2001) 0.82
Dopamine and dobutamine in pediatric therapy. Pharmacotherapy (1989) 0.82
The safety and antiviral effect of protease inhibitors in children. Pharmacotherapy (2001) 0.81
Effect of intravenous flow rate and injection site on in vitro delivery of chloramphenicol succinate and in vivo kinetics. J Pediatr (1981) 0.81
Tobramycin kinetics in newborn infants. J Pediatr (1983) 0.81
Pharmacokinetics and cerebrospinal fluid (CSF) concentrations of vancomycin in pediatric patients undergoing CSF shunt placement. Chemotherapy (1990) 0.81
Comparative bioavailability and pharmacokinetics of chloramphenicol after intravenous chloramphenicol succinate in premature infants and older patients. Dev Pharmacol Ther (1983) 0.80
Palatability of 14 over-the-counter antacids. Am Pharm (1994) 0.80
Variations in glycerol kinetics in Reye's syndrome. Clin Pharmacol Ther (1981) 0.80
Juvenile amaurotic family idiocy with cherry-red spot and cataract. Indian J Ophthalmol (1973) 0.80
Rimantadine: a clinical perspective. Ann Pharmacother (1995) 0.80
Comparative palatability of 22 liquid antacids. Aliment Pharmacol Ther (2000) 0.80
Dopamine pharmacokinetics in critically ill newborn infants. Eur J Clin Pharmacol (1991) 0.80
Clinical use of fluoroquinolones in children. Ann Pharmacother (2000) 0.80
Response to initial griseofulvin therapy in pediatric patients with tinea capitis. Ann Pharmacother (1997) 0.80
Duration of penicillin prophylaxis in sickle cell anemia: issues and controversies. Pharmacotherapy (2000) 0.79
A comparative study of anti-fungal drugs in mycotic corneal ulcer. Indian J Ophthalmol (1987) 0.79
Effect of histamine H2-receptor antagonists on vitamin B12 absorption. Ann Pharmacother (1992) 0.79
Trovafloxacin: a new fluoroquinolone. Ann Pharmacother (1999) 0.79
Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection. Am J Health Syst Pharm (2000) 0.79
Pharmacotherapy of lower limb diabetic ulcers. J Am Geriatr Soc (2000) 0.79
Efficacy of itraconazole in children with Trichophyton tonsurans tinea capitis. J Am Acad Dermatol (1998) 0.79
High-performance liquid chromatographic determination of cephalexin in human plasma, urine and saliva. J Chromatogr (1981) 0.79
Simultaneous determination of chloramphenicol and its succinate ester by high-performance liquid chromatography. J Chromatogr (1981) 0.79
Stability of dopamine hydrochloride injection in the presence of dobutamine hydrochloride, tolazoline hydrochloride, and theophylline injections. J Perinatol (1990) 0.78
Sedation with meperidine and midazolam in pediatric patients undergoing endoscopy. Eur J Clin Pharmacol (1994) 0.78
Pharmacokinetics of gabapentin in paediatric patients with uncontrolled seizures. J Clin Pharm Ther (2004) 0.78
Chloramphenicol: new perspectives on an old drug. Drug Intell Clin Pharm (1982) 0.78
Absorption of theophylline from the small and large intestine of the neonatal piglet. Eur J Drug Metab Pharmacokinet (1994) 0.78
Stability of ceftriaxone sodium in intravenous solutions. Am J Hosp Pharm (1983) 0.78
Dirithromycin: a new macrolide. Ann Pharmacother (1996) 0.78
Topical ciprofloxacin for otorrhea after tympanostomy tube placement. Arch Otolaryngol Head Neck Surg (1995) 0.78
Dosage regimens of trimethoprim/sulfamethoxazole (TPM/SMX) in patients with renal dysfunction. Ann Pharmacother (1995) 0.78
Ceftriaxone kinetics and cerebrospinal fluid penetration in infants and children with meningitis. Chemotherapy (1986) 0.78
Aerosolized furosemide in the treatment of acute respiratory distress and possible bronchopulmonary dysplasia in preterm neonates. Ann Pharmacother (2000) 0.77
Interaction between ciprofloxacin and rifampin. Ann Pharmacother (1999) 0.77
Prevention and treatment of osteoporosis in the cystic fibrosis population. J Pediatr Health Care (2001) 0.77
Haemophilus influenzae type B conjugate vaccines. Ann Pharmacother (1992) 0.77
Pharmacokinetics of cefotaxime and its active metabolite in children with renal dysfunction. Antimicrob Agents Chemother (1991) 0.77
Ceftriaxone: a third-generation cephalosporin. Drug Intell Clin Pharm (1985) 0.76